The latest news on MS treatments, research and specialist services.
MS Trust news
News from the MS Trust
Views and comment
MS Trust staff, MS health professionals and people with MS offer their perspectives on hot topics in the world of MS
Our free, quarterly newsletter for people with multiple sclerosis, their family and friends and supporters of the MS Trust.
Read our latest news
We wish the best of luck to our 54 runners for the London Marathon on Sunday and share details of our cheering points.
- Eating and MS
- Life expectancy measured
- Vehicle leasing affected by benefit changes
- Lemtrada and listeria
Iona Creedon, who was diagnosed with MS 10 years ago, has started a new blog all about gardening and MS called Gardening within liMitS. Here she talks about the inspiration behind it, reveals plans for her own garden, and shares some green-fingered wisdom.
The Scottish Medicines Consortium (SMC) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.
Today the MS Trust is launching its Put MS on the Map campaign, helping raise awareness of the vital role MS nurses play in supporting people with MS to live life to the full.
Join Bradford MS specialist nurse Liz Watson and take to the skies at our Big Blue Jump in Lancashire to support people living with MS.
Charlotte from Hampshire explains how a clear out at home kick-started a car boot sale campaign to help others who have MS.
- Ocrelizumab approved in US for relapsing and progressive MS
- Kidney and bladder stone risk
- ADHD in children of women with MS
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
- Anxiety and the link to depression
- Anxiety and psychosocial factors
- Invisible disability toilet signs
- Trigeminal neuralgia at onset of MS
Sign up to our Northamptonshire Big Blue Jump before Wednesday 5 April and sign up a friend for FREE!
Functional electrical stimulation (FES) is a treatment that applies small electrical charges to the leg to improve mobility if you have have difficulties with walking arising from damage in your brain or spinal cord. In this video we talk to our two MS Trust trustees, Sarah Joiner who has MS herself and uses a FES device, and Christine Singleton, who is a clinical specialist physiotherapist .
First comes the crying and the sleepless nights, then there’s the troublesome toddler years, and then, before you know it, your house is shaking from the door-slamming of a surly teen. Parenthood, whatever stage you’re at, is never easy, and definitely never dull. But when you’re attempting to raise a child while coping with the unpredictability of MS, it throws up a whole new set of challenges. Here are five top tips for juggling parenthood and MS.
Sarah took part in the 15-mile Belvoir Challenge walk in memory of her mum who had MS.
- Early treatment with disease modifying drugs
- Contraceptives and relapses
- Neurological services declining
- Access to neurologists
- Myelin repair research
- Caroline Wyatt and stem cell therapy
- Daclizumab (Zinbryta) approved in England and Wales
- Delayed acceptance of NICE approved drugs
- Prescription charge rises
NICE (National Institute for Health and Care Excellence) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
Two new reports published this week have highlighted the problems facing people trying to access neurological services in the UK
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
- Surgery to open up narrowed veins not effective in MS
- Kadeena Cox on MS
- Runner with MS sets herself 1000km challenge
Canadian researchers have presented preliminary results from a clinical study which suggest that surgical treatment to unblock veins draining the brain and spinal cord is not effective in treating MS.